International Journal of Research and Reports in Hematology

  • About
    • About the Journal
    • Submissions & Author Guideline
    • Accepted Papers
    • Editorial Policy
    • Editorial Board Members
    • Reviewers
    • Propose a Special Issue
    • Reprints
    • Subscription
    • Membership
    • Publication Ethics and Malpractice Statement
    • Digital Archiving Policy
    • Contact
  • Archives
  • Indexing
  • Publication Charge
  • Submission
  • Testimonials
  • Announcements
Advanced Search
  1. Home
  2. Archives
  3. 2019 - Volume 2 [Issue 1]
  4. Original Research Article

Submit Manuscript


Subscription



  • Home Page
  • Author Guidelines
  • Editorial Board Member
  • Editorial Policy
  • Propose a Special Issue
  • Membership

Long-Term Evaluation of Imatinib´s Effect on Bone Marrow Fibrosis in Patients with Chronic Myeloid Leukemia

  • Hosny Badrawy Hamed
  • Asmaa Mohamed Zahran
  • Adel Gomaa
  • Noha Gaber Sayed
  • Ahmed Makboul

International Journal of Research and Reports in Hematology, Page 1-12

Published: 16 March 2019

  • View Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract


Background: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm (MPN) that originates in an abnormal pluripotent stem cell [1]. At diagnosis, all cases of CML have the characteristic t(9;22) translocation that results in the Ph chromosome [2]. Marked bone marrow (BM) fibrosis at the time of diagnosis and worsening BM fibrosis while the patient is receiving therapy are markers of CML disease progression and poor prognosis [3]. A significant advance in the treatment of CML was achieved with the introduction of imatinib [4]. Imatinib has an independent anti-fibrotic effect on BM of CML patients [5].


Aim of the Study: We assessed BM fibrosis in CML patients treated with imatinib.


Patients and Methods: This retrospective study was done on 46 patients with CML from 2012 to 2014 treated with imatinib. Assessment of reticulin fibrosis in CML patients treated with imatinib was done using reticulum staining kit.


Results: Thirty-three patients (71.7%) of the 46 patients in our study showed progression of BM fibrosis after one year of treatment with imatinib.


Conclusion: Our findings indicate that imatinib may be associated with progression of BM fibrosis in CML patients.


Keywords:
  • Chronic myeloid leukemia
  • imatinib
  • bone marrow fibrosis.
  • Full Article - PDF
  • Review History

How to Cite

Hamed, H., Zahran, A., Gomaa, A., Sayed, N., & Makboul, A. (2019). Long-Term Evaluation of Imatinib´s Effect on Bone Marrow Fibrosis in Patients with Chronic Myeloid Leukemia. International Journal of Research and Reports in Hematology, 2(1), 1-12. Retrieved from https://journalijr2h.com/index.php/IJR2H/article/view/30093
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Abstract View: 2424 times
    PDF Download: 1008 times

Download Statistics

  • Linkedin
  • Twitter
  • Facebook
  • WhatsApp
  • Telegram
Make a Submission / Login
Information
  • For Readers
  • For Authors
  • For Librarians
Current Issue
  • Atom logo
  • RSS2 logo
  • RSS1 logo


© Copyright 2010-Till Date, International Journal of Research and Reports in Hematology. All rights reserved.